Tags : Target

Evotec Collaborates with Rappta Therapeutics to Focus on Oncology Target

Shots: Evotec to receive research funding & is eligible for milestones. Evotec will support Rappta’s program of developing small molecule activators of the enzyme PP2A The collaboration leverages Evotec’s integrated platform for drug discovery and development and its oncology expertise coupled with state-of-the-art technologies PP2A is a serine/threonine phosphatase that functions as a tumor suppressor […]Read More

Takeda Collaborates with Engitix to Target Fibrotic Liver Diseases

Shots: Engitix to receive up front with additional payments based on the confirmation and functional validation of selected targets and is eligible to receive $500M as preclinical, development, regulatory and commercial milestones along with royalties on sales of therapies Takeda to get the exclusive rights to develop and commercialize the candidate emerges from the collaboration. […]Read More

Evotec and Centogene Expand their Collaboration to Target Gaucher Disease

Shots: The two companies will work together to research, discover, and develop therapeutic options related to the deficiency of the protein GBA which is a gene linked to Gaucher disease The collaboration will combine Evotec’s iPSC platform and drug discovery and development capabilities with Centogene’s global rare disease platform, including iPSC lines The collaboration follows […]Read More

Vir and Alnylam Expand their 2017 License Agreement to Target

Shots: The companies expand their existing collaboration to develop & commercialize RNAi therapies targeting SARS-CoV-2 utilizing Alnylam’s advances in lung delivery of novel conjugates of siRNA along with Vir’s infectious disease expertise Vir will be responsible for all development and commercialization of any selected DCs while Alnylam has an option to share equal profits & […]Read More

Bayer Signs a Three Year Multi Target AI-based Agreement with

Shots: Exscientia to get up to $266.2M including upfront, research payments and clinical milestones plus royalties on sales. Bayer to get rights for the developed therapies under collaboration   The partners will focus on early research projects combining Exscientia’s AI drug discovery platform and drug design know-how with Bayer’s data and drug discovery capabilities for […]Read More